Quantcast
Last updated on April 18, 2014 at 15:05 EDT

Latest ViroPharma Incorporated Stories

2014-02-25 08:31:20

EXTON, Pennsylvania, February 25, 2014 /PRNewswire/ -- ViroPharma Incorporated today announced the results of its tender offer (the "Convertible Notes Tender Offer") pursuant to which each holder of the 2.00% Convertible Senior Notes Due 2017 (the "Convertible Notes") had the right (the "Fundamental Change Repurchase Right") to require ViroPharma to repurchase all of such holder's Convertible Notes, or any portion thereof that is a multiple of $1,000 principal amount, on...

2014-02-13 08:31:20

DUBLIN, February 13, 2014 /PRNewswire/ -- - Shire expects similar Non GAAP earnings per ADS growth in 2014 - Shire (LSE: SHP, NASDAQ: SHPG) announces unaudited results for the year to December 31, 2013. Financial Highlights Full Year 2013 (1) $4,757 Product sales million +12%...

2014-01-15 12:25:40

DUBLIN, January 15, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has waived the Office of Fair Trading (OFT) approval condition to the announced tender offer for all of the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM). As a result of the waiver, the transaction is no longer conditional on OFT approval, and Shire expects to complete the tender offer on January 24, 2014 following the currently scheduled expiration time, subject...

2014-01-10 04:20:37

DUBLIN, January 10, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that it has extended the expiration of its previously announced tender offer by a wholly owned subsidiary of Shire for all of the outstanding common shares of ViroPharma Incorporated (NASDAQ: VPHM) until midnight, New York City time, on Thursday, January 23, 2014 (one minute after 11:59 p.m., New York City time, on January 23, 2014). The tender offer had previously been scheduled to expire...

2013-12-11 08:29:47

DUBLIN, Ireland, December 11, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to its previously announced tender offer by a wholly owned subsidiary of Shire for all outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM) expired at 11:59 p.m., Eastern U.S. time, on December 10, 2013. The expiration of the HSR waiting period satisfies one of the...

2013-11-12 08:35:43

- Data presented at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting - EXTON, Pa., Nov. 12, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM), an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced results of a new quality of life data analysis from the randomized, placebo-controlled pivotal prophylaxis study of...

2013-11-11 04:21:09

Earnings accretive, revenue growth-enhancing acquisition DUBLIN and EXTON, Pennsylvania, November 11, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) and ViroPharma Incorporated (NASDAQ: VPHM) today announce that their Boards of Directors have unanimously approved, and the companies have entered into, a merger agreement pursuant to which Shire will acquire all the outstanding shares of the rare disease company ViroPharma for $50 per share in cash, for a total...

2013-11-06 16:30:36

EXTON, Pa., Nov. 6, 2013 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced it will present data relating to the quality of life in patients with Hereditary Angioedema (HAE) receiving nanofiltered C1 Inhibitor (C1 INH-nf) replacement therapy for prophylaxis as well as data relating to the Angioedema Clinical Epidemiology Testing Initiative for the study of Hereditary Angioedema (ACET) at the 70th American College of Allergy, Asthma and Immunology (ACAAI) Annual...

2013-10-31 08:33:00

- Cinryze® (C1 Esterase Inhibitor [Human]) North American Net Sales Guidance Raised to $395 to $405 Million - EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2013. Net sales were $113 million for the third quarter ended September 30, 2013, as compared to $91 million in the same three months of 2012. The increase was primarily driven by growth in U.S. Cinryze sales. Cinryze U.S....

2013-10-28 12:26:37

EXTON, Pa., Oct. 28, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2013 are expected to be released on Thursday, October 31, 2013 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2013 third quarter financial results along with other business. The press release...